Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Androstenedone SCHEMBL134061 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL1144460 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL12430773 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL3758714 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL14450072 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL10597170 | 0.99 | CYP19A1 (0.97) | CYP19A1CYP3A4LMNAMAPT | |
| Androstenedone SCHEMBL4266758 | 0.92 | CYP19A1 (0.84) | CYP19A1CYP3A4LMNA | |
| SCHEMBL6897786 | 0.88 | CYP19A1 (0.79) | CYP19A1CYP3A4LMNAMAPT | |
| SCHEMBL8491921 | 0.86 | CYP19A1 (0.76) | CYP19A1CYP3A4LMNA | |
| SCHEMBL6999301 | 0.86 | CYP19A1 (0.76) | CYP19A1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142561-B9 | PROCESS FOR PREPARING AROMATASE INHIBITORS | SCINOPHARM TAIWAN LTD (TW) | 2014-02-19 | — | — | EP | disclosed |
| US-8541609-B2 | Exemestane and its intermediates and methods of making the same | CEDARBURG PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2142561-B1 | PROCESS FOR PREPARING AROMATASE INHIBITORS | SCINOPHARM TAIWAN LTD (TW) | 2013-06-26 | — | — | EP | disclosed |
| EP-1709062-B9 | EXEMESTANE AND ITS INTERMEDIATES AND METHODS OF MAKING THE SAME | CEDARBURG PHARMACEUTICALS INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8288571-B2 | Process for preparing aromatiase inhibitor exemestane | CADILA HEALTHCARE LIMITED (IN) | 2012-10-16 | — | — | US | disclosed |
| US-8288571-B2 | Process for preparing aromatiase inhibitor exemestane | CADILA HEALTHCARE LIMITED (IN) | 2012-10-16 | — | — | US | disclosed |
| US-20120209016-A1 | Exemestane and its Intermediates and Methods of Making the Same | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2012-08-16 | — | — | US | disclosed |
| US-8183401-B2 | Aromatase inhibitor; deprotonation | CEDARBURG PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-1709062-B1 | EXEMESTANE AND ITS INTERMEDIATES AND METHODS OF MAKING THE SAME | CEDARBURG PHARMACEUTICALS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110028711-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-02-03 | — | — | US | disclosed |
| US-20080275259-A1 | Process for preparing aromatase inhibitors | SCINOPHARM TAIWAN, LTD (TW) | 2008-11-06 | — | — | US | disclosed |
| US-20080275259-A1 | Process for preparing aromatase inhibitors | SCINOPHARM TAIWAN, LTD (TW) | 2008-11-06 | — | — | US | disclosed |
| US-20080234505-A1 | Exemestane and Its Intermediates and Methods of Making the Same | CEDARBURG PHARMACEUTICALS, INC (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080070881-A1 | Prostate Cancer Treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070881-A1 | Prostate Cancer Treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080009472-A1 | Prostate Cancer Treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009472-A1 | Prostate Cancer Treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080004250-A1 | Compounds and Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004250-A1 | Compounds and Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| WO-2007041564-A2 | (S)-6-METHYLOXAALKYL EXEMESTANE COMPOUNDS AND RELATED METHODS OF USE | ENDECE, LLC (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070881-A1 | Prostate Cancer Treatment | AR, KLK3, PTGER1 | CYP19A1 49/4885CYP3A4 1241/4885LMNA 3897/4885 |
| US-20080275259-A1 | Process for preparing aromatase inhibitors | CYP19A1, HSD17B11, CYP17A1 | CYP19A1 1/4885CYP3A4 22/4885LMNA 1671/4885 |
| US-20080234505-A1 | Exemestane and Its Intermediates and Methods of Making the Same | CYP19A1, ESR1, CYP21A2 | CYP19A1 1/4885CYP3A4 35/4885LMNA 2022/4885 |
| US-20080009472-A1 | Prostate Cancer Treatment | AR, KLK3, PTGER1 | CYP19A1 49/4885CYP3A4 1241/4885LMNA 3897/4885 |
| US-20110028711-A1 | Unsaturated Steroid Compounds | PTGER1, AR, PTGES3 | CYP19A1 35/4885CYP3A4 1126/4885LMNA 2659/4885 |
| US-20120209016-A1 | Exemestane and its Intermediates and Methods of Making the Same | CYP19A1, ESR1, CYP21A2 | CYP19A1 1/4885CYP3A4 35/4885LMNA 2022/4885 |
| US-20080004250-A1 | Compounds and Formulations | AR, PTGER1, NR5A1 | CYP19A1 18/4885CYP3A4 706/4885LMNA 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.